"
Team:SupBiotech-Paris/Conclusion3
From 2009.igem.org
(Difference between revisions)
Enguerrand (Talk | contribs) |
Enguerrand (Talk | contribs) |
||
| Line 1: | Line 1: | ||
{{Template:Supbiotechcss.css}} | {{Template:Supbiotechcss.css}} | ||
{{Template:SupbiotechparisEn}} | {{Template:SupbiotechparisEn}} | ||
| - | |||
| - | |||
| - | |||
| + | [[Team:SupBiotech-Paris/Conclusion3#drapeau|Back to top]] | ||
<html> | <html> | ||
Revision as of 10:43, 17 October 2009
Project
Introduction Current therapies Gene therapies DVS Concept Tissue Vector Cell Vector Therapeutic plasmid Conclusion Implementation Tissue targeting Antitumor action Treatment modeling Conclusion
Ressources
BioBricks Material & Method Bibliography
Ethics & Safety
